Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist, which is a new antidiabetic drug that has been studied to show therapeutic benefits in non-insulin dependent diabetics and in patients with preexisted heart disease. Type 2 diabetes often leads to cardiovascular complications especially atherosclerosis which can lead to a myocardial infarction. GLP-1 receptors are widely presented in different tissues including the cardiovascular and pancreatic tissues. GLP-1 agonist performs many functions including stimulating pancreatic beta-cells to release insulin, suppressing glucagon secretion, promoting blood glucose balance, delaying gastric emptying, and decreasing appetite. Excess sugar in the blood can prevent glucose absorption into cells
The mechanism of action of dulaglutide involves activation of GLP-1 receptor; a membrane-bound cell surface receptor coupled to adenyl cyclase in β cells. Increase in intracellular cells leads to a glucose-dependent release of insulin. Reduction in the secretion of glucagon and slow gastric emptying is done by Dulaglutide (K). Continued administration of dulaglutide increases fasting insulin and C-peptide concentrations, thus reducing fasting glucagon concentrations. Healthy patients as well as adults with type 2 diabetes have similar dulaglutide pharmacokinetics. It occurs slowly, but is well absorbed into the systemic circulation, thus reaching a maximum plasma concentration.
Melbourne is located in the south-eastern part of mainland Australia, within the state of Victoria. Geologically, it is built on the confluence of Quaternary lava flows to the west, Silurian mudstones to the east, and Holocene sand accumulation to the southeast along Port Phillip. The southeastern suburbs are situated on the Selwyn fault which transects Mount Martha and Cranbourne.
Sequoyah (ᏍᏏᏉᏯ) was born in Monroe County, Tennessee which is east of the Chillhowee Mountain. He lives about 8 miles away from New Echota, the old Cherokee Nation Capital. Sequoyah was born around 1760 - 1765 and died about 1843. Sequoyah’s mother's name is Wut-teh she belongs to the red paint clan, his father had left before Sequoyah was born, and he is believed to be known as George Gist, a German paddler of Nathaniel Gist, an English fur trader. The English name that was given to him was George Gist, his Cherokee name (S-si-qua-ya or ᏍᏏᏉᏯ) meant “pig’s foot”.
Becky Gulsvig Begins Her Fall Appearance in the 'School of Rock ' on Broadway .
Cynthia is a 65 year old African American female diagnosed with type 2 diabetes mellitus, diabetic peripheral neuropathy, hypertension, kidney disease, hyperlipidemia and hypothyroidism. She is on glipizide 5 mg po daily to treat her type 2 diabetes. Cynthia revisited the clinic soon after the initiation of the treatment with symptoms of shakiness, sweating, chills, clamminess, lightheadedness and moderately severe headache. In this case study, Cynthia is exhibiting the symptoms of hypoglycemia as she is on sulfonylurea therapy. Sulfonylureas, such as glipizide commonly used as a second-line of therapy in patients with Type 2 Diabetes Mellitus (T2DM), promote insulin release independent of prevailing glucose value and as a result,
Sequoyah was a Cherokee Indian who created the Cherokee language. He was born around 1760 to 1765 in the village of Tuskeegee, Tennessee. His mother was the daughter of a Cherokee chief, and his father was a Virginia fur-trader. Sequoyah was married to a Cherokee and was a silversmith. Because the white soldiers could read and write letters, Sequoyah became inspired to create a written and spoken language during War of 1812, and he taught it to his daughter Ayoka. Sequoyah was a very important figure in Cherokee life.
Selim I also known as “The Grim” was the third son born to Bayezid II, he came into power by getting rid of his father. Selim began to wage war on other Muslim states because he believed that the other Muslim states were condoning heresy. Selim I first killed thousands of Shia Muslim people before he started a war with the Persian Shia king named Isma’il. Selim I and his army also began to move towards Mesopotamia and finally in 1514 Selim’s army conquered the Safavid army. This was easy for Selim I because his army was equipped with muskets and weapons such as guns, while the Safavid army had older weapons like the bow and arrow, blades, and spears. After defeating the Safavid army he then moved on to start a war with the Mameluk leaders that
She also has a mineral named after her: Selenite. Selenite is a form of gypsum with an appearance of a white translucent crystal. Selenite can be used in window panes, but is mainly seen in jewelry.
Diabetes is a growing concern and health challenge for the American people (b). Diabetes is a condition in which the body cannot react to insulin appropriately or either cannot produce insulin efficiently (w). “Without a properly functioning insulin signaling system, blood glucose levels become elevated and other metabolic abnormalities occur, leading to the development of serious, disabling complications” (w). There are numerous forms of diabetes amongst the nation, however, there are three main forms of diabetes. Most people have heard of type one diabetes, type two diabetes, and gestational diabetes because they are common. Type two diabetes deals with a resistance to insulin, while
Glyburide is another generic medication used in the management of diabetes mellitus type 2. Two trade names of this drug are DiaBeta and Glynase. The chemical name is 1-[ [p-[2-(5-chloro-o-anisamido) ethyl]phenyl]-sulfonyl]-3-cyclohexylurea. Doses up to 0.75-12 mg/day can be given as a single dose or divided doses. The circulation of the glyburide is that protein binding is extensive and half-life is 10 hours. It is excreted through the renal and biliary system. Glyburide acts as an oral blood glucose lowering drug. The drugs uses include binding and activating the sulfonylurea receptor 1, which causes depolarization. This results in an increase in intracellular calcium in the cells and stimulation of insulin release. Major drug interactions are noted between glyburide and
Diabetes is a growing but preventable health concern in the United States.1 It is a problem in the body where blood glucose levels rise higher than normal.1 According to the facts released by the American Diabetes Association in 2013, 25.8 million Americans (8.3%) have diabetes 2 and approximately 90% of all cases of diabetes worldwide are considered type 2 diabetes.3 Type 2 diabetes is a progressive disease where the body cannot use insulin properly and the patient ends up using an oral hypoglycemic agent.1 One of the many classes of medications to help manage diabetes is sulfonylureas, including glyburide and glipizide. These drugs close K-ATP channels on Beta cell membranes and cause the pancreas to release more insulin to lower blood sugar.4 Both glipizide and glyburide are metabolized in the liver5, have high protein binding5, and can decrease hemoglobin A1c (HbA1c) up to 1%-2%.6 According to the Health Insurance Association of America, health insurance is defined as "coverage that provides for the payments of benefits as a result of sickness or injury".7 Insurance companies always strive to achieve their target glycemic goal via the most effective and cost effective therapeutic strategy.8 A literature search was conducted to find data on the benefits of converting patients from glyburide to glipizide to find out why insurance prefers the switch.
Type 2 diabetes is a polygenic, complex disease that has become a worldwide health crisis. According to the World Health Organization over 422 million people in the world had this disease in 2014 (1), the Center for Disease Control and Prevention stated that in the United States alone 29 million people had diabetes in 2014 (2). While the genetic predisposition contributing to the diabetes phenotype is not fully understood to date it still remains an area of active research. There are also various environmental factors that contribute stress to the glucose homeostasis system that provide a different approach in understanding this disease. Comprehending the pathogenesis of the disease has been an area of constant research for decades. There is hope that pharmaceutical developments can follow along and find medical treatments that can target the key pathogenic elements of this disease.
Diabetes is a disease where the body is unable to produce or use insulin effectively. Insulin is needed for proper storage and use of carbohydrates. Without it, blood sugar levels can become too high or too low, resulting in a diabetic emergency. It affects about 7.8% of the population. The incidence of diabetes is known to increase with age. It’s the leading cause of end-stage renal disease in the US, and is the primary cause of blindness and foot and leg amputation. It is known to cause neuropathy in up to 70% of diabetic patients. Individuals with diabetes are twice as likely to develop cardiovascular disease. There are two types of diabetes: Type 1 and Type 2.
Diabetes Mellitus is “a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. It is a disease which is caused by the insufficient insulin secretion or decrease in the peripheral effects of insulin. It is a serious problem in terms of morbidity and mortality. The hyperglycemia is associated with long term damage, dysfunction and failure of various organs especially the eyes, kidneys, nerves, heart and blood vessels. It’s associated with many complications which includes blindness of the eyes and amputations of the extremities. It is also associated with neuropathy, retinopathy, and cardiovascular diseases which lead to mortalities.
Diabetes is a systemic disease caused by a decrease in the secretion of insulin or reduced sensitivity or responsiveness to insulin by target tissue. (Beale, et al., 2011) The incidence of diabetes is growing rapidly in the United States and worldwide. An estimated 347 million people around the world are afflicted with diabetes. (Whalen, et al., 2012) According to World Health Organization (WHO), Diabetes prevalence among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. It is the major cause of blindness, kidney failure, heart attack, stroke and limbic amputation. World Health Organization (WHO) projects that diabetes will be the 7th leading cause of death in 2030. It is a complex and costly disease that can affect nearly every organ in the body and result in devastating consequences. The leading cause of non-traumatic lower extremity amputations, renal failure, and blindness in working-age adults, diabetes is also a major cause of premature mortality, stroke, cardiovascular disease, peripheral vascular disease, congenital malformations, perinatal mortality, and disability. (Cefalu, 2000) Insulin therapy and oral hypoglycemic agents have demonstrated improvement in glycaemic control. However, Insulin therapy has some disadvantages such as ineffectiveness following oral administration, short shelf life, of the need for constant refrigeration, and fatal hypoglycaemia, in the event of excess dosage.